The relationship of FcgammaRIIIa genotype to degree of B cell depletion by rituximab in the treatment of systemic lupus erythematosus - PubMed (original) (raw)
Clinical Trial
doi: 10.1002/art.10764.
Affiliations
- PMID: 12571855
- DOI: 10.1002/art.10764
Free article
Clinical Trial
The relationship of FcgammaRIIIa genotype to degree of B cell depletion by rituximab in the treatment of systemic lupus erythematosus
Jennifer H Anolik et al. Arthritis Rheum. 2003 Feb.
Free article
Abstract
Objective: Despite wide use of the anti-CD20 monoclonal antibody rituximab in the treatment of B cell lymphomas, the mechanism by which it causes B cell depletion remains a subject of controversy. As part of an ongoing phase I/II trial of rituximab in the treatment of systemic lupus erythematosus (SLE), we sought to determine whether the effectiveness of B cell depletion was influenced by polymorphisms of Fc receptors (FcR) on effector cells.
Methods: During rituximab treatment of 12 SLE patients, B cell depletion was monitored as a function of the serum rituximab level and FcgammaRIIa and FcgammaRIIIa genotypes at baseline and at 1 month and 2 months after treatment. FcR genotypes were determined by polymerase chain reaction. Serum levels of rituximab were measured by enzyme-linked immunosorbent assay (ELISA). B lymphocyte percentages were assessed by flow cytometry.
Results: B cell depletion was highly variable in this patient cohort, with B cell percentages at the 1-2-month posttreatment nadir ranging from undetectable (<0.1 cell/microl) to 16% ( approximately 30 cells/microl) of the total peripheral blood lymphocytes. At 2 months posttreatment, B cell percentages were highly correlated with both the serum rituximab level and the FcgammaRIIIa genotype (R(2) = 0.75, P = 0.002). The FcgammaRIIIa genotype was a significant independent predictor of the efficacy of B cell depletion (P = 0.019).
Conclusion: These results highlight the potential variability of B cell depletion by rituximab in the treatment of autoimmune disease and indicate that Fc receptors are an important determinant of that variability. The findings further suggest the importance of antibody-dependent cell-mediated cytotoxicity and/or apoptosis induction via FcgammaRIIIa-expressing effector cells in the mechanism of B cell depletion by this widely used monoclonal antibody.
Similar articles
- B cell depletion as a novel treatment for systemic lupus erythematosus: a phase I/II dose-escalation trial of rituximab.
Looney RJ, Anolik JH, Campbell D, Felgar RE, Young F, Arend LJ, Sloand JA, Rosenblatt J, Sanz I. Looney RJ, et al. Arthritis Rheum. 2004 Aug;50(8):2580-9. doi: 10.1002/art.20430. Arthritis Rheum. 2004. PMID: 15334472 Clinical Trial. - Rituximab improves peripheral B cell abnormalities in human systemic lupus erythematosus.
Anolik JH, Barnard J, Cappione A, Pugh-Bernard AE, Felgar RE, Looney RJ, Sanz I. Anolik JH, et al. Arthritis Rheum. 2004 Nov;50(11):3580-90. doi: 10.1002/art.20592. Arthritis Rheum. 2004. PMID: 15529346 Clinical Trial. - Variability in the biological response to anti-CD20 B cell depletion in systemic lupus erythaematosus.
Albert D, Dunham J, Khan S, Stansberry J, Kolasinski S, Tsai D, Pullman-Mooar S, Barnack F, Striebich C, Looney RJ, Prak ET, Kimberly R, Zhang Y, Eisenberg R. Albert D, et al. Ann Rheum Dis. 2008 Dec;67(12):1724-31. doi: 10.1136/ard.2007.083162. Epub 2008 Feb 4. Ann Rheum Dis. 2008. PMID: 18250115 Clinical Trial. - [Rituximab in systemic lupus erythematosus. Part I. Theoretical basis].
Kardynał A, Rudnicka L. Kardynał A, et al. Pol Merkur Lekarski. 2010 Aug;29(170):131-4. Pol Merkur Lekarski. 2010. PMID: 20842829 Review. Polish. - Rituximab: a promising therapy in systemic lupus erythematosus.
Thatayatikom A, White AJ. Thatayatikom A, et al. Autoimmun Rev. 2006 Jan;5(1):18-24. doi: 10.1016/j.autrev.2005.05.006. Epub 2005 Jun 13. Autoimmun Rev. 2006. PMID: 16338207 Review.
Cited by
- Influence of FCGR3A genotype on the therapeutic response to rituximab in rheumatoid arthritis: an observational cohort study.
Kastbom A, Cöster L, Arlestig L, Chatzidionysiou A, van Vollenhoven RF, Padyukov L, Rantapää-Dahlqvist S, Saevarsdottir S. Kastbom A, et al. BMJ Open. 2012 Sep 22;2(5):e001524. doi: 10.1136/bmjopen-2012-001524. Print 2012. BMJ Open. 2012. PMID: 23002160 Free PMC article. - Rituximab for refractory Wegener's granulomatosis: report of a prospective, open-label pilot trial.
Keogh KA, Ytterberg SR, Fervenza FC, Carlson KA, Schroeder DR, Specks U. Keogh KA, et al. Am J Respir Crit Care Med. 2006 Jan 15;173(2):180-7. doi: 10.1164/rccm.200507-1144OC. Epub 2005 Oct 13. Am J Respir Crit Care Med. 2006. PMID: 16224107 Free PMC article. Clinical Trial. - Treatment with rituximab in benign and malignant hematologic disorders in children.
Giulino LB, Bussel JB, Neufeld EJ; Pediatric and Platelet Immunology Committees of the TMH Clinical Trial Network. Giulino LB, et al. J Pediatr. 2007 Apr;150(4):338-44, 344.e1. doi: 10.1016/j.jpeds.2006.12.038. J Pediatr. 2007. PMID: 17382107 Free PMC article. Review. No abstract available. - Update on rituximab.
Eisenberg R. Eisenberg R. Ann Rheum Dis. 2005 Nov;64 Suppl 4(Suppl 4):iv55-7. doi: 10.1136/ard.2005.042648. Ann Rheum Dis. 2005. PMID: 16239389 Free PMC article. Review. No abstract available. - Rituximab therapy for juvenile-onset systemic lupus erythematosus.
Nwobi O, Abitbol CL, Chandar J, Seeherunvong W, Zilleruelo G. Nwobi O, et al. Pediatr Nephrol. 2008 Mar;23(3):413-9. doi: 10.1007/s00467-007-0694-9. Epub 2007 Dec 19. Pediatr Nephrol. 2008. PMID: 18097688 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials